2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1349

Treat to Target: What’s the Target?
Abstract Number: 1350

Ultrasound Detected Tenosynovitis in Rheumatoid Arthritis Patients in Clinical Remission
Abstract Number: 1351

Minimal Clinically Important Improvement (MCII) of RAPID3 (ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3), an INDEX of ONLY Patient Self-Report Scores in Rheumatoid Arthritis (RA): Similar Performance to DAS28 and CDAI
Abstract Number: 1352

The Relevance of Elevated CRP As an Inclusion Criterion in Clinical Trials in Patients with Rheumatoid Arthritis
Abstract Number: 1353

Is Joint Damage Due to Secondary Osteoarthritis (OA) Clinically As Important As Inflammation in Contemporary Management of Rheumatoid Arthritis (RA)?
Abstract Number: 1354

Fatigue, Poor Health and Mood Disturbance Persist in Rheumatoid Arthritis and Psoriatic Arthritis Patients Despite Disease Remission: The OPAL Deeper Study
Abstract Number: 1355

14-3-3η: Useful for More Than the Diagnosis of Rheumatoid Arthritis?
Abstract Number: 1356

Is ACPA-Positive RA Still a More Severe Disease Than ACPA-Negative RA? a Longitudinal Cohort Study in RA-Patients Treated from 2000 Onwards
Abstract Number: 1357

Anti-Cyclic Citrullinated Peptide Antibody Positive Rheumatoid Arthritis Patients with Comorbid Post-Traumatic Stress Disorder Have Higher Serum Cytokine Expression
Abstract Number: 1358

Relationship between Serum Protein Pattern and High Disease Activity in Patients with Rheumatoid Arthritis
Abstract Number: 1359

M-DAS28, M-SDAI and M-CDAI Performance in a Cohort of RA Patients with and without Concomitant Fibromyalgia
Abstract Number: 1360

Validation of the Health Assessment Questionnaire-Upper Extremity (HAQUP) in Patients with Rheumatoid Arthritis
Abstract Number: 1361

How Often Do Rheumatologists Use Valid Prognostic Factors of Rheumatoid Arthritis? the Progresar Project
Abstract Number: 1362

Assessing the Quality, Reliability and Readability of Online Health Information Regarding Rheumatoid Arthritis
Abstract Number: 1363

Disease Duration and Shared Epitope, but Not Smoking History, Are Associated with Peptidylarginine Deiminase 4-Antibody Development in Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].